Dynamk Capital Announces New General Partner, Reinhard Vogt

Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science companies, announces today the addition of Reinhard Vogt as a new General Partner & Managing Director, effective immediately.  Reinhard joins the fund currently led by Daniella Kranjac, Founding Partner, and Mario Kranjac, Founding Partner and General Counsel.  Reinhard comes to Dynamk Capital with a wealth of industry knowledge, technology deal-side expertise and numerous technology licenses, acquisitions and integrations at one of the industry’s largest players, Sartorius AG.  What this means to investors and portfolio companies is a winning combination of commercial and operational support derived from Reinhard’s experience with more than a dozen high-profile, accretive deals throughout his time at Sartorius.   He was instrumental in building and transforming their filtration business from $30 million in the 90s, to what is now today the Sartorius Bioprocess Business of around $1.2 billion.   

Reinhard commented “Dynamk Capital stood out to me from the very start as it met an underserved market providing vital capital to life science companies making the leap from early stage to commercial success before exiting.  I am excited to work with the Dynamk team again and apply this innovative approach to broader opportunities in the market”. 

Earlier in his career Reinhard was instrumental in transforming Sartorius’ strategy to become the leader in single-use bioprocessing technologies, essentially revolutionizing how biologics are manufactured.  His track record includes technology licenses and acquisitions ranging from the Stedim SA and B. Braun Biotech transactions to more recent deals including TAP Biosystems, Cellca, BioOutsource and Umetrics.  He served as Executive VP and Member of the Board of Sartorius AG for over 10 years and as Director of several companies of the Sartorius Group. Reinhard has a unique talent and proven track record of value creation by targeting companies and technologies that when integrated create a solution aimed at speeding the development and commercialization of therapeutics.  The end result is a success story where biotech pioneers get access to the best in class technologies and technology providers realize maximum commercial value.   

Decades of navigating the competitive life sciences landscape are the basis of Dynamk’s instinctive ability to not only identify winning technologies but to strategically map out gaps they can fill in the offering of companies for exit strategies.  This combined with Dynamk’s vast network ensures portfolio companies are well positioned from the start to exit with maximum returns.     

About Dynamk Capital

Dynamk Capital LLC is a venture capital firm investing in early stage life sciences companies.  Dynamk’s investment strategy is centered on identifying companies developing disruptive technologies, tools and services that enable the full biopharma continuum across discovery, development and manufacturing of therapeutics.  The Dynamk team includes experienced life science entrepreneurs, investors, advisors and subject matter experts.  Please visit www.dynamk.vc for more information.

Dynamk Announces Advisory Team


Dynamk Capital, a venture fund providing early stage and growth capital to innovative Life Science tools and service providers, announces their all-star list of advisors.  Dynamk has paved the way for startups with disruptive technologies and services to gain vital capital to reach the next phase.   Dynamk’s partners have leveraged its network of fellow entrepreneurs, industry thought leaders and disrupters in creating a team of advisors to help ensure sound strategic decisions aimed at maximizing returns for investors.     

When assembling the team, Dynamk sought domain experts with deep technical knowledge, a proven track record of successful businesses, and most of all, a keen sense of where the industry is trending.  The advisor list is a who’s who of widely respected experts in their field:

·       Kevin Bailey, PhD.; Former VP, Process Development and Preclinical Manufacturing, Regeneron.  Kevin brings his experience in preclinical manufacturing and process development areas where he has had extensive experience developing new products, processes and evaluating new technologies. 

·       Barry Buckland, PhD.; CEO, BiologicB, LLC and former VP, Bioprocess R&D, Merck and Co., Inc. In addition to his years of experience in bioscience and discovery, Barry is a constant source of early stage technologies through his vast industry network and as President of Engineering Conferences International (ECI).

·       Anthony Maddaluna; Former President, Pfizer Global Supply.  Anthony brings his experience in diligence and evaluating the merits of new technologies to be deployed into cGMP manufacturing operations. 

·       Gustavo Mahler, PhD.; CEO, CMC Biologics / AGC Asahi Glass.  Gustavo is an expert in biologic development and manufacturing; in his most recent role, he is directly responsible for evaluating and implementing cutting edge technologies. 

Barry Buckland commented, “Dynamk Capital has an important role to fill in the Biopharmaceutical industry by making strategic investments to accelerate commercialization of innovative tools and technologies.“

General Partner Daniella Kranjac commented, “The team of advisors will bring insights on best practices and operational excellence needed for early stage companies.  They are also well aware of all the key players likely for exiting to and how innovative technologies can fill gaps in their portfolios.  This will ensure that companies which are highly likely to succeed are brought into the fund and will be best positioned to exit with maximum returns.” 

Kevin Bailey commented, “Dynamk Capital has the rare opportunity to help accelerate research, development and manufacturing in the biopharma industry by identifying companies with disruptive new technologies and facilitating getting them into the hands of those who will bring new products and hope to patients.” 

Dynamk Invests in FloDesign Sonics, Game-Changer for Cell Therapy Production

Englewood Cliffs, NJ, January 10, 2018 - Dynamk Capital, a life sciences venture capital fund, today announced an exciting new investment in advancing the commercial production of CAR T and immunotherapies by adding FloDesign Sonics to its growing portfolio. Dynamk’s portfolio companies provide technologies and services that enable biopharmaceutical companies around the world to develop therapeutics faster and produce them more economically.

Dynamk Capital led the Series A2 round alongside other investors. FloDesign Sonics, a life science company, applies acoustic wave separation to challenges in cell handling…

Dynamk Invests in Envisagenics A.I. Drug Discovery

Picture1 copy.jpg

Englewood Cliffs, NJ, November 28, 2017 - Dynamk Capital, a recently launched life sciences venture capital fund, today announced an exciting new investment in early drug discovery by adding Envisagenics, Inc. to its growing portfolio. 

Dynamk Capital invested $500,000 in Envisagenics, leading the $2.25 million seed round alongside other investors. Envisagenics, a life science company applies artificial intelligence to the genetic sequence of patients to discover new therapies.  Its proprietary cloud-based discovery platform SpliceCoreTM uses machine learning to prioritize new drug target candidates from patients’ RNA. 

Daniella Kranjac, co-founder and managing director of Dynamk Capital, said, “Envisagenics is disrupting traditional drug discovery through applied machine learning and AI.  We are excited to see the commercialization of SpliceCore enable biopharma leaders to accelerate critical discovery efforts for life-saving therapeutics.”

Dynamk Capital Announces First Closing

Dynamk Capital Announces First Closing

Dynamk Capital Announces First Closing and Launch of Life Sciences Venture Fund

ENGLEWOOD CLIFFS, NJ, Sept. 26, 2017 /PRNewswire/ -- Dynamk Capital has announced a first close for its venture fund providing early stage capital to innovative companies providing tools, technologies and services within the Life Sciences sector.   The fund is on track for a final close in 2018 and expects to invest in 8-10 companies over the next several years.  Since founding in 2016, Dynamk has been actively cultivating deal flow as well as relationships with limited partners and strategic investors. 

“We are excited about the strong support of the fund at this early stage, especially among leaders in the sector,” said Daniella Kranjac, Managing Partner of Dynamk Capital.  “Investors in our fund will be provided with the opportunity to engage in the discovery and production of life-saving therapies, and ultimately making these medicines more accessible.”  

Daniella Kranjac joins Stevens Institute of Technology Board of Trustees

Daniella Kranjac of Dynamk Consulting LLC and Dynamk Capital Advisors joins the Stevens Institute of Technology Board of Trustees as a charter member.  

About Stevens:  Stevens Institute of Technology, The Innovation University® is a premier, private research university in Hoboken, NJ overlooking the Manhattan skyline.  Stevens is home to three national research centers of excellence, as well as joint research programs focused on innovation in: healthcare & medicine, sustainable energy, financial systems, defense & security and STEM education.